Literature DB >> 14711881

Phenotypic clustering in MPZ mutations.

Michael E Shy1, Agnes Jáni, Karen Krajewski, Marina Grandis, Richard A Lewis, Jun Li, Rosemary R Shy, Janne Balsamo, Jack Lilien, James Y Garbern, John Kamholz.   

Abstract

Myelin protein zero (MPZ) is a member of the immunoglobulin gene superfamily with single extracellular, transmembrane and cytoplasmic domains. Homotypic interactions between extracellular domains of MPZ adhere adjacent myelin wraps to each other. MPZ is also necessary for myelin compaction since mice which lack MPZ develop severe dysmyelinating neuropathies in which compaction is dramatically disrupted. MPZ mutations in humans cause the inherited demyelinating neuropathy CMT1B. Some mutations cause the severe neuropathies of infancy designated as Dejerine-Sottas disease, while others cause a 'classical' Charcot-Marie-Tooth (CMT) disease Type 1B (CMT1B) phenotype with normal early milestones but development of disability during the first two decades of life. Still other mutations cause a neuropathy that presents in adults, with normal nerve conduction velocities, designated as a 'CMT2' form of CMT1B. To correlate the phenotype of patients with MPZ mutations with their genotype, we identified and evaluated 13 patients from 12 different families with eight different MPZ mutations. In addition, we re-analysed the clinical data from 64 cases of CMT1B from the literature. Contrary to our expectations, we found that most patients presented with either an early onset neuropathy with signs and symptoms prior to the onset of walking or a late onset neuropathy with signs and symptoms at around age 40 years. Only occasional patients presented with a 'classical' CMT phenotype. Correlation of specific MPZ mutations with their phenotypes demonstrated that addition of either a charged amino acid or altering a cysteine residue in the extracellular domain caused a severe early onset neuropathy. Severe neuropathy was also caused by truncation of the cytoplasmic domain or alteration of an evolutionarily conserved amino acid. Taken together, these data suggest that early onset neuropathy is caused by MPZ mutations that significantly disrupt the tertiary structure of MPZ and thus interfere with MPZ-mediated adhesion and myelin compaction. In contrast, late onset neuropathy is caused by mutations that more subtly alter myelin structure and which probably disrupt Schwann cell-axonal interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711881     DOI: 10.1093/brain/awh048

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  69 in total

1.  Charcot-Marie-Tooth disease subtypes and genetic testing strategies.

Authors:  Anita S D Saporta; Stephanie L Sottile; Lindsey J Miller; Shawna M E Feely; Carly E Siskind; Michael E Shy
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

2.  Current Therapy for Charcot-Marie-Tooth Disease.

Authors:  Marina Grandis; Michael E Shy
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.598

3.  Charcot-Marie-Tooth disease: genetic and clinical spectrum in a Spanish clinical series.

Authors:  Rafael Sivera; Teresa Sevilla; Juan Jesús Vílchez; Dolores Martínez-Rubio; María José Chumillas; Juan Francisco Vázquez; Nuria Muelas; Luis Bataller; José María Millán; Fancesc Palau; Carmen Espinós
Journal:  Neurology       Date:  2013-09-27       Impact factor: 9.910

Review 4.  Inherited neuropathies: an update.

Authors:  Anna Sagnelli; Giuseppe Piscosquito; Davide Pareyson
Journal:  J Neurol       Date:  2013-09-24       Impact factor: 4.849

5.  A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy.

Authors:  Marian A J Weterman; Vincenzo Sorrentino; Paul R Kasher; Marja E Jakobs; Baziel G M van Engelen; Kees Fluiter; Marit B de Wissel; Aleksander Sizarov; Gudrun Nürnberg; Peter Nürnberg; Noam Zelcer; H Jurgen Schelhaas; Frank Baas
Journal:  Hum Mol Genet       Date:  2011-10-19       Impact factor: 6.150

Review 6.  [Genetics of neuropathies].

Authors:  B Gess; A Schirmacher; P Young
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

7.  Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.

Authors:  Agnes Patzkó; Yunhong Bai; Mario A Saporta; István Katona; Xingyao Wu; Domenica Vizzuso; M Laura Feltri; Suola Wang; Lisa M Dillon; John Kamholz; Daniel Kirschner; Fazlul H Sarkar; Lawrence Wrabetz; Michael E Shy
Journal:  Brain       Date:  2012-12       Impact factor: 13.501

Review 8.  Diagnosis of Charcot-Marie-Tooth disease.

Authors:  Isabel Banchs; Carlos Casasnovas; Antonia Albertí; Laura De Jorge; Mónica Povedano; Jordi Montero; Juan Antonio Martínez-Matos; Victor Volpini
Journal:  J Biomed Biotechnol       Date:  2009-10-08

9.  Charcot-marie-tooth disease: seventeen causative genes.

Authors:  Jung-Hwa Lee; Byung-Ok Choi
Journal:  J Clin Neurol       Date:  2006-06-20       Impact factor: 3.077

10.  Two novel missense mutations in the myelin protein zero gene causes Charcot-Marie-Tooth type 2 and Déjérine-Sottas syndrome.

Authors:  Geir J Braathen; Jette C Sand; Michael B Russell
Journal:  BMC Res Notes       Date:  2010-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.